Mindset Pharma Past Earnings Performance
Past criteria checks 0/6
Mindset Pharma's earnings have been declining at an average annual rate of -10.6%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 124.8% per year.
Key information
-10.6%
Earnings growth rate
9.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 124.8% |
| Return on equity | n/a |
| Net Margin | -78.8% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Mindset Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 8 | -6 | 4 | 9 |
| 31 Dec 22 | 8 | -5 | 3 | 9 |
| 30 Sep 22 | 6 | -9 | 6 | 7 |
| 30 Jun 22 | 4 | -17 | 10 | 7 |
| 31 Mar 22 | 2 | -21 | 12 | 7 |
| 31 Dec 21 | 0 | -21 | 12 | 6 |
| 30 Sep 21 | 0 | -16 | 10 | 4 |
| 30 Jun 21 | 0 | -12 | 4 | 2 |
| 31 Mar 21 | 0 | -7 | 2 | 1 |
Quality Earnings: MSET is currently unprofitable.
Growing Profit Margin: MSET is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MSET's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MSET's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSET is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: MSET's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.